



Aratana Maintains Their Momentum with Additional Regulatory Successes

Aratana had a banner year in 2016 with three FDA-approvals and has continued their regulatory successes by gaining a conditional licensure from the USDA in late-2017 and marketing authorization in Europe earlier this year.

The USDA granted a Conditional License for their Canine Osteosarcoma Vaccine, Live Listeria Vector (AT-014) for the treatment of dogs diagnosed with osteosarcoma, one year of age or older in December 2017. The novel immunotherapy uses a listeria based antigen delivery system that activates cytotoxic T-cells to capitalize on the dog's immune system. As required by USDA to progress from conditional licensure to full licensure, Aratana plans to conduct an extended field study in a clinical setting and anticipates initiating the study in early 2018 at approximately two dozen veterinary oncology practice groups across the United States who participate in the study.

In January, Aratana, along with their collaborator Elanco Animal Health, announced GALLIPRANT® (grapiprant tablets) was granted marketing authorization in the European Union for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Grapiprant, the active ingredient in Galliprant, is a non-steroidal non-cyclooxygenase inhibiting anti-inflammatory drug.